Opioid Dependence Treatment (ODT) flexi-audit (5 patients)

EA hours: 1.5
MO hours: 5
RP hours: 1.5
Total hours: 8
Male patient considering pharmacotherapy treatment for opioid dependence
On this page

    This is the 5 patient version of this clinical audit.

    Click here if you would like to do the 10 or 15 patient versions of this clinical audit. 

    Note: you can't swap between audits, once you start one audit, you need to complete that audit before any CPD hours will be allocated.

     

    On any given day in Australia, about 53,000 people are receiving pharmacotherapy treatment for opioid dependence.1 In 2023, more patients received a buprenorphine formulation than methadone for the first time.1 

    This clinical audit begins with a 1.5-hour pre-learning activity exploring case studies in opioid use disorder, current options for opioid dependency treatment, and the use of opioid pharmacotherapies in medication assisted treatment of opioid dependence (MATOD). Risks and benefits of latest opioid agonist treatments will be covered, with a focus on long-acting injectable buprenorphine (LAIB) products. 

    After completing the pre-learning activity, GPs will perform a clinical audit of 5 patients currently receiving MATOD in the form of sublingual buprenorphine, or methadone. Patient management will be reviewed against Australian ODT guidelines, and GPs will assess whether the patient could benefit from switching to a long-acting injectable buprenorphine (LAIB) medication. Guidance is provided on how to undertake this switch, either in the primary care setting or with appropriate referral for specialist care.       

    1. Australian Institute of Health and Welfare (2024) National Opioid Pharmacotherapy Statistics Annual Data collection, AIHW, Australian Government, accessed 17 December 2024.

     

    Learning outcomes

    On completion of this educational activity participants will be able to:
    Identify current treatment options for patients diagnosed with opioid dependence.
    Inform patients about the benefits and risks of long-acting injectable buprenorphine (LAIB) and use shared decision making to decide if they would benefit from switching to an LAIB.
    Apply clinical guidelines for initiating an LAIB in a patient currently taking sublingual buprenorphine.
    Demonstrate how to initiate an LAIB in a patient currently taking <30 mg methadone or how to refer such a patient to their local Drug and Alcohol Service for initiation of an LAIB.
    Demonstrate how to refer a patient currently on ≥30mg methadone to their local Drug and Alcohol Service for review, and outline key components of the referral letter.

    Opioid Dependence Treatment (ODT) flexi-audit (5 patients) - Predisposing activity
    Opioid Dependence Treatment (ODT) flexi-audit (5 patients) - Education
    Opioid Dependence Treatment (ODT) flexi-audit (5 patients) - Audit introduction
    Opioid Dependence Treatment (ODT) flexi-audit (5 patients) - Patient entry
    Opioid Dependence Treatment (ODT) flexi-audit (5 patients) - Reflective activity
    Opioid Dependence Treatment (ODT) flexi-audit (5 patients) - Reinforcing acticity
    Opioid Dependence Treatment (ODT) flexi-audit (5 patients) - Evaluation
    Sponsored by
    RACGP and ACRRM CPD logo